Changzhou Qianhong Biopharma Co Ltd

The company maintains a strong liquidity position, with a current ratio of 8.47 and cash and equivalents amounting to 491.05 million CNY. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce its financial stability. Free cash flow of 147.12 million CNY indicates robust operating cash generation. Profitability metrics are favorable, with a return on equity of 14.41% and a return on assets of 12.91%. These figures exceed the typical thresholds for pharmaceutical firms, suggesting efficient use of equity and assets. The gross profit margin of 58.0% (911.63 million CNY on 1.57 billion CNY revenue) and operating margin of 29.0% (455.53 million CNY) also reflect strong cost control and pricing power. The company operates as a single business segment, with no disclosed geographic diversification. Revenue is entirely attributed to domestic operations, indicating a high concentration risk. No major international markets or revenue streams are reported. Growth appears stable, with a current FY EPS of 0.32 CNY and a mean analyst estimate of 0.33 CNY for the next period. While no explicit revenue growth rate is provided, the positive analyst sentiment and absence of dilution or liquidity risks suggest a conservative but steady outlook. Risk factors are minimal, with no immediate liquidity or dilution concerns. The company has no long-term debt, and shares outstanding remain unchanged between basic and diluted measures. No recent filings or transcripts indicate material risk events or strategic shifts. Recent events include a strong analyst recommendation of 1.00 (strong buy) with one strong-buy rating and no downgrades. The EPS estimate of 0.33 CNY aligns closely with the actual 0.32 CNY, indicating stable earnings performance and limited volatility.